Dermavant Sciences Inc., of Phoenix, a subsidiary of Roivant Sciences Ltd., said it agreed to purchase rights to tapinarof, an aryl hydrocarbon receptor modulating agent in development for psoriasis and atopic dermatitis, from London-based Glaxosmithkline plc.